Scientists in Germany claim to have developed a nasal vaccine that can stop Covid-19 infections in the nose and throat, where the virus first takes hold. The vaccine is made with a weakened form of the coronavirus and was tested on hamsters, achieving "sterilizing immunity" and preventing illness.
The vaccine was shown to be more effective than other types of vaccines in animal studies, including an mRNA-based vaccine and one that uses an adenovirus. Researchers believe that the live but weakened version of the virus worked better because it mimicked a natural infection.
This approach is not new; it has been used for decades against other diseases such as anthrax and rabies. The researchers manipulated the genetic material in the virus to make it harder for cells to translate, creating an "unreadable" text that can't be read by the immune system without making the person sick.
The vaccine's potential lies in its ability to boost mucosal immunity, which is better at dealing with new variants of the virus. The researchers believe that this approach could prevent the spread of infection and make future versions of the virus less threatening.
While the results are promising, more testing is needed before the vaccine can be used on humans. The study began in 2021 before the Omicron variant emerged, but the live but weakened nasal vaccine still performed better than other vaccines against Omicron.
At least four nasal vaccines for Covid-19 have reached late-stage testing in people, according to the World Health Organization's vaccine tracker. These vaccines use different approaches, including harmless adenoviruses and live attenuated viruses.
However, the development of nasal vaccines has been slow and challenging due to the high costs involved. The COVID-19 pandemic highlights the need for effective respiratory infection prevention measures, particularly against strains like Omicron that can easily evade existing immunity.
In reality, researchers acknowledge that there's still much work to be done to develop a pan-coronavirus vaccine that induces mucosal immunity and is long-lived.
The vaccine was shown to be more effective than other types of vaccines in animal studies, including an mRNA-based vaccine and one that uses an adenovirus. Researchers believe that the live but weakened version of the virus worked better because it mimicked a natural infection.
This approach is not new; it has been used for decades against other diseases such as anthrax and rabies. The researchers manipulated the genetic material in the virus to make it harder for cells to translate, creating an "unreadable" text that can't be read by the immune system without making the person sick.
The vaccine's potential lies in its ability to boost mucosal immunity, which is better at dealing with new variants of the virus. The researchers believe that this approach could prevent the spread of infection and make future versions of the virus less threatening.
While the results are promising, more testing is needed before the vaccine can be used on humans. The study began in 2021 before the Omicron variant emerged, but the live but weakened nasal vaccine still performed better than other vaccines against Omicron.
At least four nasal vaccines for Covid-19 have reached late-stage testing in people, according to the World Health Organization's vaccine tracker. These vaccines use different approaches, including harmless adenoviruses and live attenuated viruses.
However, the development of nasal vaccines has been slow and challenging due to the high costs involved. The COVID-19 pandemic highlights the need for effective respiratory infection prevention measures, particularly against strains like Omicron that can easily evade existing immunity.
In reality, researchers acknowledge that there's still much work to be done to develop a pan-coronavirus vaccine that induces mucosal immunity and is long-lived.